<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Sequenom News Release</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=irol-news&amp;nyo=0</link><description>A Collection of Sequenom News Release</description><language>en-us</language><category>Uncategorized</category><lastBuildDate>Tue, 09 Feb 2010 13:42:10 GMT</lastBuildDate><item><title>Sequenom Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostic Test</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1385437</link><description><![CDATA[SAN DIEGO, Feb 09, 2010 /PRNewswire via COMTEX/ --  Sequenom, Inc. (Nasdaq: SQNM), today announced an exclusive worldwide licensing agreement with Optherion, Inc. Under the agreement, Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD).
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)

The license agreement covers extensive intellectual property rights for the most significant AMD-related genetic variants that have been confirmed in multiple clinical studies around t...]]></description><category>Uncategorized</category><guid isPermaLink="false">1385437_NEWS</guid><pubDate>Tue, 09 Feb 2010 13:34:14 GMT</pubDate></item><item><title>Sequenom Announces Launch of SensiGene Fetal RHD Genotyping Test</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1383114</link><description><![CDATA[First Commercial Test using SEQureDx Technology for Determining Rhesus D IncompatibilitySAN DIEGO, Feb 04, 2010 /PRNewswire via COMTEX/ --  Sequenom, Inc. (Nasdaq: SQNM) today announced the launch of the SensiGene(TM) Fetal RHD Genotyping test by Sequenom's CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM). This is the company's first laboratory developed test powered by its SEQureDx(TM) technology.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)

In the United States, there are approximately 528,000 pregnancies in Rhesus D (RhD) negative women every year, and almost all of these women could benefit from an assessment of the ...]]></description><category>Uncategorized</category><guid isPermaLink="false">1383114_NEWS</guid><pubDate>Thu, 04 Feb 2010 13:33:24 GMT</pubDate></item><item><title>Sequenom Announces Addition to Clinical Advisory Board</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1380442</link><description><![CDATA[SAN DIEGO, Jan 28, 2010 /PRNewswire via COMTEX/ -- Sequenom, Inc. (Nasdaq: SQNM) today announced that Dr. Wolfgang Holzgreve has joined the company's Clinical Advisory Board. Dr. Holzgreve currently serves as Director and Chairman of the Board of Directors at the University Hospital Freiburg, Germany. 
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO) 
"We are very pleased to welcome Wolfgang to our Clinical Advisory Board," said Dr. Allan Bombard, chief medical officer at Sequenom. "Adding Wolfgang as an active member to our renowned group of advisors will considerably expand our noninvasive prenatal diagnostic experience - an important step as we ramp up our global clinical a...]]></description><category>Uncategorized</category><guid isPermaLink="false">1380442_NEWS</guid><pubDate>Thu, 28 Jan 2010 21:11:00 GMT</pubDate></item><item><title>Sequenom Announces Settlement Agreement In Shareholder Class Action Lawsuit</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1375563</link><description><![CDATA[SAN DIEGO, Jan 15, 2010 /PRNewswire via COMTEX/ -- Sequenom, Inc. (Nasdaq: SQNM), announced today the entry of a settlement agreement which will resolve the consolidated securities class action lawsuits, In re Sequenom, Inc. Securities Litigation, Master File No: 3:09-cv-00921-LAB-WMC. The defendants have agreed to pay $14 million, which will be funded by insurance proceeds. Additionally the company has agreed to issue to the plaintiffs' class a number of shares of Sequenom common stock. These shares shall constitute 9.95% of the total shares then outstanding, subject to certain limitations. The company has also agreed to adopt or continue its implementation of changes and additions to certa...]]></description><category>Uncategorized</category><guid isPermaLink="false">1375563_NEWS</guid><pubDate>Fri, 15 Jan 2010 13:32:00 GMT</pubDate></item><item><title>Sequenom Appoints Two New Board Members</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1366500</link><description><![CDATA[SAN DIEGO, Dec 16, 2009 /PRNewswire-FirstCall via COMTEX/ -- Sequenom, Inc. (Nasdaq: SQNM), today announced the appointment of Dr. Kenneth Buechler and Mr. David Pendarvis to its board of directors.
(Logo:  http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)

Kenneth F. Buechler, Ph.D., was president, chief scientific officer and co-founder of Biosite Incorporated. From 1988 to 1994, Dr. Buechler was Biosite's director of chemistry. Prior to forming Biosite, Dr. Buechler was a senior research scientist for the diagnostics research and development group at Hybritech Incorporated in San Diego. Dr. Buechler received his doctorate in biochemistry and his bachelor's degree in chemistry from...]]></description><category>Uncategorized</category><guid isPermaLink="false">1366500_NEWS</guid><pubDate>Wed, 16 Dec 2009 13:35:00 GMT</pubDate></item><item><title>Sequenom Announces New Clinical Advisory Board Member</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1361638</link><description><![CDATA[







SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM), today announced that Dr. Yves Ville has joined the company's Clinical Advisory Board. Dr. Ville is a prominent obstetrician-gynecologist and currently serves as professor and chairman of the department of obstetrics and fetal medicine at Necker-Enfants-Malades Hospital at the Paris Descartes University.



(Logo:  http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)



"I am delighted that Yves has agreed to join our Clinical Advisory Board," said Dr. Allan Bombard, chief medical officer at Sequenom. "It's important to have the highest caliber experts available to help guide our numerous clin...]]></description><category>Uncategorized</category><guid isPermaLink="false">1361638_NEWS</guid><pubDate>Thu, 03 Dec 2009 13:04:00 GMT</pubDate></item><item><title>Sequenom Reports Third Quarter 2009 Financial Results</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1353137</link><description><![CDATA[SAN DIEGO, Nov. 9 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM) today reported its financial results for the quarter ended September 30, 2009.



(Logo:  http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)



Third Quarter Results


    --  Total revenue for the third quarter of 2009 was $9.2 million, compared
        with $11.6 million for the third quarter of 2008.
    --  Cost of product and service revenue for the third quarter of 2009 was
        $2.7 million, compared with $4.5 million for the third quarter of 2008.
    --  Gross margin for the third quarter of 2009 was 71%, compared with 61%
        for the third quarter of 2008, reflecting higher consumab...]]></description><category>Uncategorized</category><guid isPermaLink="false">1353137_NEWS</guid><pubDate>Mon, 09 Nov 2009 21:01:00 GMT</pubDate></item><item><title>SEQUENOM Announces Date of Third Quarter 2009 Financial Results and Conference Call</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1351148</link><description><![CDATA[SAN DIEGO, Nov 04, 2009 /PRNewswire-FirstCall via COMTEX/ -- SEQUENOM, Inc. (Nasdaq: SQNM), will report third quarter 2009 and year-to-date financial results after market close on Monday, November 9, 2009.  The company will conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern Time) on the same day.
Conference Call Information:

Domestic callers: 1-800-299-9086

International callers: +1-617-786-2903

Passcode: 72106407

Webcast information: Visit http://ir.sequenom.com.

The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at www....]]></description><category>Uncategorized</category><guid isPermaLink="false">1351148_NEWS</guid><pubDate>Wed, 04 Nov 2009 21:02:00 GMT</pubDate></item><item><title>Sequenom Announces Paul Maier to Become Interim Chief Financial Officer</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1346345</link><description><![CDATA[



SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM), today announced that Paul V. Maier has been appointed as the company's interim chief financial officer effective November 10, 2009, reporting directly to the company's interim chief executive officer and chairman of the board, Harry F. Hixson, Jr., Ph.D.



(Logo:  http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)



Prior to the effective date of Mr. Maier's appointment as interim chief financial officer, Mr. Maier will act as a consultant to the company.



"I am delighted that Paul has agreed to join Sequenom as our interim CFO," said Dr. Hixson. "His wealth of experience, including over 2...]]></description><category>Uncategorized</category><guid isPermaLink="false">1346345_NEWS</guid><pubDate>Mon, 26 Oct 2009 20:06:00 GMT</pubDate></item><item><title>SEQUENOM Announces Completion of Independent Investigation</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1336063</link><description><![CDATA[SEQUENOM to Hold Conference Call Today at 2:00 p.m. Pacific Time
SAN DIEGO, Sept. 28 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. (Nasdaq: SQNM) today announced the completion of the independent investigation by a special committee of independent directors related to the test data and results for the company's noninvasive prenatal test for Trisomy 21 (Down syndrome).  The independent counsel engaged by the special committee interviewed over 40 witnesses and reviewed over 300,000 documents and emails.




Based on the special committee's work and recommendations, the independent members of the company's board of directors have concluded that as a result of the company's attempted transition...]]></description><category>Uncategorized</category><guid isPermaLink="false">1336063_NEWS</guid><pubDate>Mon, 28 Sep 2009 20:03:00 GMT</pubDate></item><item><title>SEQUENOM Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1332995</link><description><![CDATA[SAN DIEGO, Sept. 17 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. (Nasdaq: SQNM) today announced that the company's first laboratory developed test, the SensiGene(TM) Cystic Fibrosis (CF) Carrier Screening test, has been launched. This test is available exclusively through the Sequenom Center for Molecular Medicine, a next-generation CLIA (Clinical Laboratory Improvement Amendments, 1988) molecular diagnostic laboratory and a wholly-owned subsidiary of Sequenom, Inc.



(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)



The SensiGene CF Carrier Screening Test




    --  This innovative test screens for 103 mutations and five variants,
        including the 23 mutation...]]></description><category>Uncategorized</category><guid isPermaLink="false">1332995_NEWS</guid><pubDate>Thu, 17 Sep 2009 13:03:00 GMT</pubDate></item><item><title>SEQUENOM Announces Partnership with Geneworks for Sales &amp; Marketing of MassARRAY Systems and Applications in Australia</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1329708</link><description><![CDATA[

Untitled Document




SAN DIEGO, Calif.-September 9th, 2009-SEQUENOM, Inc. (NASDAQ: SQNM) and GeneWorks 
Pty. Ltd. today announced an exclusive sales agency agreement under which GeneWorks 
will assist SEQUENOM in expanding its sales & marketing presence in Australia. 
The partnership will initially focus on new business development activity across 
Australia. GeneWorks has significant experience and a strong reputation in the 
supply of genomics technologies and reagents and is an Australian manufacturer 
of high quality oligonucleotides and offers a range of genetic analysis services 
including Next Generation Sequencing services.
"Given our introduction of the new MassARR...]]></description><category>Uncategorized</category><guid isPermaLink="false">1329708_NEWS</guid><pubDate>Wed, 09 Sep 2009 04:00:00 GMT</pubDate></item><item><title>SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1318252</link><description><![CDATA[SAN DIEGO, Aug 06, 2009 /PRNewswire-FirstCall via COMTEX/ -- SEQUENOM, Inc. (Nasdaq: SQNM), today reported its financial results for the quarter ended June 30, 2009.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)

Second Quarter Results


    --  Total revenue for the second quarter of 2009 was $9.2 million, compared
        with $12.8 million for the second quarter of 2008. The decrease from the
        comparable period last year was primarily due to softness in capital
        expenditure in the bioresearch market, resulting in lower sales of
        MassARRAY((R)) systems.
    --  Cost of product and service revenue for the second quarter of 2009 was
        $3...]]></description><category>Uncategorized</category><guid isPermaLink="false">1318252_NEWS</guid><pubDate>Thu, 06 Aug 2009 20:03:00 GMT</pubDate></item><item><title>SEQUENOM Announces August 6 Webcast of Financial and Other Business Results</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1314458</link><description><![CDATA[    San Diego, July 30 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. (Nasdaq:
SQNM), will report second quarter 2009 and year-to-date financial results
after market close on Thursday, August 6, 2009.  The company will conduct a
conference call and an audio webcast at 1:30 pm Pacific Time (4:30 pm Eastern
Time) on the same day.


    Conference Call Information:
    Domestic callers: 1-800-706-7749
    International callers: +1-617-614-3474
    Passcode: 42079558

    Webcast information: Visit http://ir.sequenom.com.

    The webcast is also being distributed through the Thomson StreetEvents
Network to both institutional and individual investors. Individual investors
can listen to...]]></description><category>Uncategorized</category><guid isPermaLink="false">1314458_NEWS</guid><pubDate>Thu, 30 Jul 2009 18:02:00 GMT</pubDate></item><item><title>SEQUENOM Announces Launch of MassARRAY Compact 96 System</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1312555</link><description><![CDATA[--New System Delivers Fast, Efficient, Cost-Effective Solution for Clinical Research     SAN DIEGO, July 27, 2009 /PRNewswire-FirstCall via COMTEX/ -- SEQUENOM, Inc. (Nasdaq: SQNM) today announced the launch of the MassARRAY(R) Compact 96 system.
(Logo:  http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)

This generation of the MassARRAY system now addresses the needs of lower throughput laboratories. The combination of features of the new MassARRAY Compact 96 system - accuracy, sensitivity, and now the ability to cost-effectively run fewer samples - make this an ideal system for use in basic and clinical laboratories.

With the addition of the MassARRAY Compact 96 system SEQUENOM n...]]></description><category>Uncategorized</category><guid isPermaLink="false">1312555_NEWS</guid><pubDate>Mon, 27 Jul 2009 20:32:00 GMT</pubDate></item><item><title>University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1307133</link><description><![CDATA[  New Study Uncovers Significant Proportion of Potential False Negatives in
         Widely Used HPV DNA Test which could lead to Cervical Cancer





    SAN DIEGO and ANN ARBOR, Mich., July 13 /PRNewswire-FirstCall/ -- Results
from a study published by the University of Michigan have shown that as many
as 15% of women in the study group determined to be negative for the presence
of human papillomavirus (HPV) in the cervix, via the most commonly used test
for HPV DNA, may actually be infected with the virus at clinically relevant
viral loads. PCR-MS detected the presence of high-risk HPV in nearly half
(46.7%) of women who tested negative by the Hybrid Capture 2 (HC2) test, whi...]]></description><category>Uncategorized</category><guid isPermaLink="false">1307133_NEWS</guid><pubDate>Mon, 13 Jul 2009 20:32:00 GMT</pubDate></item><item><title>SEQUENOM Reports First Quarter 2009 Financial Results</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1282231</link><description><![CDATA[    SAN DIEGO--(BUSINESS WIRE)--Apr. 29, 2009--
      SEQUENOM, Inc. (NASDAQ: SQNM) today reported its financial
      results for the quarter ended March 31, 2009.
    

      SEQUENOM reported first quarter 2009 revenues of $8.7 million, compared
      with revenues of $10.6 million reported for the first quarter of 2008.
      The decrease in revenues for the first quarter was primarily due to a
      decrease in system sales and services in the company’s genetic analysis
      business. Net loss for the first quarter of 2009 was $17.5 million, or
      $0.29 per share, compared with $8.6 million, or $0.19 per share, for the
      first quarter of 2008. The increase in net loss...]]></description><category>Uncategorized</category><guid isPermaLink="false">1282231_NEWS</guid><pubDate>Wed, 29 Apr 2009 20:41:00 GMT</pubDate></item><item><title>SEQUENOM Announces Delay in Launch of SEQureDx Trisomy 21 Test</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1282219</link><description><![CDATA[    SAN DIEGO--(BUSINESS WIRE)--Apr. 29, 2009--
      SEQUENOM, Inc. (NASDAQ: SQNM) announced today that the expected
      launch of its SEQureDx™ Down syndrome test is delayed, due to the
      discovery by company officials of employee mishandling of R&D test data
      and results. Accordingly the company is no longer relying on the
      previously announced R&D test data and results. SEQUENOM has not changed
      its plans to develop in parallel its RNA- and DNA-based methods for the
      Down syndrome test and will endeavor to have a validated test in the
      fourth quarter of 2009. Under the circumstances, and as supported by key
      clinical opinion leaders, the compa...]]></description><category>Uncategorized</category><guid isPermaLink="false">1282219_NEWS</guid><pubDate>Wed, 29 Apr 2009 20:31:00 GMT</pubDate></item><item><title>SEQUENOM Announces Cost Cutting Initiative in Genetic Analysis Business</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1280059</link><description><![CDATA[    SAN DIEGO--(BUSINESS WIRE)--Apr. 23, 2009--
      SEQUENOM, Inc. (NASDAQ: SQNM) today announced that as a result of
      the continuing weak outlook in 2009 for capital equipment sales,
      particularly in the USA, the company has implemented cost cutting
      initiatives in the Genetic Analysis (GA) business to ensure the unit
      remains financially strong and approaches cash flow breakeven. These
      measures are expected to generate increased operational efficiencies and
      reduce costs while continuing to allow SEQUENOM to serve the needs of
      its current and future genetic analysis customers. In addition, SEQUENOM
      is also repositioning the GA business ...]]></description><category>Uncategorized</category><guid isPermaLink="false">1280059_NEWS</guid><pubDate>Thu, 23 Apr 2009 19:00:00 GMT</pubDate></item><item><title>SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1279849</link><description><![CDATA[    San Diego, April 23 /PRNewswire-FirstCall/ -- SEQUENOM, Inc. (Nasdaq:
SQNM), today announced that it will report first quarter 2009 financial
results after market close on Thursday, April 30, 2009.  The company will
conduct a conference call and an audio webcast at 1:30 pm Pacific Time (4:30
pm Eastern Time) on the same day.


    Conference Call Information: 

    Domestic callers: 1 (866) 844-2998

    International callers: 1 (706) 679-9912


    Webcast information: Visit the investor relations section at
www.sequenom.com.
    The webcast is also being distributed through the Thomson StreetEvents
Network to both institutional and individual investors. Individual investo...]]></description><category>Uncategorized</category><guid isPermaLink="false">1279849_NEWS</guid><pubDate>Thu, 23 Apr 2009 12:32:00 GMT</pubDate></item><item><title>Sequenom to Present at Two Investment Community Conferences in March</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1263916</link><description><![CDATA[SAN DIEGO, Mar 09, 2009 (BUSINESS WIRE) -- Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic analysis 
      solutions, today announced that Harry Stylli, Ph.D., President and Chief 
      Executive Officer, is scheduled to present at the following investment 
      community conferences:


Barclays Capital Global Healthcare Conference on March 10th 
        at 3:45 p.m. Eastern time at Loews Miami Beach Hotel in Miami Beach.
      

29th Annual Cowen & Company Healthcare Conference on March 
        17th at 9:30 a.m. Eastern time at the Boston Marriott 
        Copley Place in Boston.
      


A live webcast of these presentations will be available on the Company's...]]></description><category>Uncategorized</category><guid isPermaLink="false">1263916_NEWS</guid><pubDate>Mon, 09 Mar 2009 11:02:00 GMT</pubDate></item><item><title>Sequenom Adopts Share Purchase Rights Plan</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1262414</link><description><![CDATA[    SAN DIEGO--(BUSINESS WIRE)--Mar. 4, 2009--
      Sequenom, Inc. (NASDAQ: SQNM) today announced that its Board of
      Directors has approved the adoption of a Share Purchase Rights Plan
      under which all stockholders of record as of the close of business on
      March 20, 2009 will receive rights to purchase shares of a new series of
      Preferred Stock.
    

      The Rights Plan is designed to enable all stockholders of Sequenom to
      realize the full value of their investment and to provide for fair and
      equal treatment for all stockholders in the event that an unsolicited
      attempt is made to acquire Sequenom. The Rights Plan has not been
      adopte...]]></description><category>Uncategorized</category><guid isPermaLink="false">1262414_NEWS</guid><pubDate>Wed, 04 Mar 2009 12:01:00 GMT</pubDate></item><item><title>Sequenom Selects PDI to Provide Sales Team for Launch of Noninvasive Prenatal Screening Tests</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1262101</link><description><![CDATA[SADDLE RIVER, N.J. & SAN DIEGO, Mar 03, 2009 (BUSINESS WIRE) -- PDI, Inc. (NASDAQ:PDII), and Sequenom Center for Molecular 
      Medicine, LLC (SCMM), a wholly owned subsidiary of Sequenom, Inc. 
      (NASDAQ:SQNM) announced today that PDI has been selected to provide the 
      sales infrastructure to launch and commercialize SCMM's noninvasive 
      prenatal genetic screening tests based on its SEQureDx(TM) technology.
Under the direction of SCMM management, PDI will support the 
      commercialization of SCMM's fetal Rhesus D genotyping test from a 
      maternal blood sample. This test will reduce the risk to the mother and 
      fetus by providing clinicians early and accu...]]></description><category>Uncategorized</category><guid isPermaLink="false">1262101_NEWS</guid><pubDate>Tue, 03 Mar 2009 14:54:00 GMT</pubDate></item><item><title>High-Throughput Genotyping of AML Patients for a Key Immune Receptor May Significantly Improve Treatment Outcome</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1257472</link><description><![CDATA[Study Results Published in Blood, Journal of the American Society of Hematology
    SAN DIEGO--(BUSINESS WIRE)--Feb. 18, 2009--
      Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic analysis
      solutions, today announced results of a large, multicenter retrospective
      study from the Children’s Hospital Oakland Research Institute and the
      University of Minnesota Cancer Center showing that donors with more
      stimulatory natural killer cell immunoglobulin-like receptor (KIR)
      haplotypes result in significantly improved treatment outcome in
      patients with acute myelogenous leukemia (AML) who received
      hematopoietic cell transplantation (HCT) th...]]></description><category>Uncategorized</category><guid isPermaLink="false">1257472_NEWS</guid><pubDate>Wed, 18 Feb 2009 12:01:00 GMT</pubDate></item><item><title>Sequenom Reports Fourth Quarter Financial Results</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1255628</link><description><![CDATA[Introduces 2009 Revenue Guidance
    SAN DIEGO--(BUSINESS WIRE)--Feb. 11, 2009--
      Sequenom, Inc. (NASDAQ: SQNM) today reported financial results
      for the three and 12 months ended December 31, 2008.
    

      “This past year was pivotal for Sequenom as we continued to advance our
      genetic analysis and molecular diagnostics businesses,” stated Harry
      Stylli, Ph.D., President and Chief Executive Officer of Sequenom. “We
      accomplished many key milestones over the last 12 months and are
      well-positioned for the launch of our SEQureDx™ Down syndrome technology
      in June. The data reported from our R&D study containing 858-patient
      samples clear...]]></description><category>Uncategorized</category><guid isPermaLink="false">1255628_NEWS</guid><pubDate>Wed, 11 Feb 2009 21:08:00 GMT</pubDate></item><item><title>Sequenom to Hold Fourth Quarter and Full Year 2008 Financial Results Conference Call on February 11</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1251739</link><description><![CDATA[    SAN DIEGO--(BUSINESS WIRE)--
      Sequenom, Inc. (NASDAQ: SQNM), a leading provider of genetic
      analysis solutions, today announced that it will release fourth quarter
      and full year 2008 financial results after market close on Wednesday,
      February 11, 2009. Sequenom management will host an investment-community
      conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to
      discuss those results and answer questions.
    

      Individuals interested in participating in the conference call may do so
      by dialing (866) 844-2998 for domestic callers, or (706) 679-9912 for
      international callers. Those interested in listening to the con...]]></description><category>Uncategorized</category><guid isPermaLink="false">1251739_NEWS</guid><pubDate>Wed, 04 Feb 2009 12:01:00 GMT</pubDate></item><item><title>Sequenom Announces Findings on Methylation Markers and RNA-SNP Markers as Presented at SMFM</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1251187</link><description><![CDATA[Company Provides Additional Details on SEQureDx Trisomy 21 Technology Performance Data
    SAN DIEGO--(BUSINESS WIRE)--
      Sequenom, Inc. (NASDAQ: SQNM) today announced new data showing
      the discovery of DNA methylation markers for Trisomy 21 (Down syndrome),
      Trisomy 18 (Edwards syndrome) and Trisomy 13 (Patau syndrome) and
      identification of chromosome RNA-SNP markers for early detection of
      Trisomies 18 and 13. The data were presented on Thursday and Friday,
      January 29 and January 30, 2009, at the 29th annual meeting of the
      Society for Maternal-Fetal Medicine (SMFM). In addition, Sequenom
      announced more information regarding the performanc...]]></description><category>Uncategorized</category><guid isPermaLink="false">1251187_NEWS</guid><pubDate>Tue, 03 Feb 2009 12:31:00 GMT</pubDate></item><item><title>Sequenom Announces New Positive Data on Down Syndrome Detection and Unveils Breakthrough DNA Approach to Prenatal Diagnostics</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1249615</link><description><![CDATA[Data Continue to Support Significant Market Potential for Sequenom Prenatal Franchise; Down Syndrome Test on Track for Launch in June 2009
    SAN DIEGO--(BUSINESS WIRE)--
      Sequenom, Inc. (NASDAQ:SQNM) today announced new positive data
      from the prospective clinical studies using the Company’s noninvasive
      SEQureDx™ technology, enabling the detection of fetal aneuploidy from
      maternal blood. The data presented today consist of 459 new, high
      prevalence samples from the prospective, blinded studies performed at
      Sequenom, bringing the total number of samples studied to 858. Based on
      the results from the total study samples, including samples as earl...]]></description><category>Uncategorized</category><guid isPermaLink="false">1249615_NEWS</guid><pubDate>Thu, 29 Jan 2009 02:44:00 GMT</pubDate></item><item><title>Sequenom Center for Molecular Medicine Collaborates with Obstetrix Medical Group to Provide Clinical Samples for LDT Validation Study</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1249459</link><description><![CDATA[Collaboration with Leading Maternal-Fetal Medicine Physician Group Signifies Further Step Toward Commercializing Trisomy 21 Test
    SAN DIEGO--(BUSINESS WIRE)--
      Sequenom, Inc. (NASDAQ:SQNM), today announced a collaboration
      with Obstetrix Medical Group, to provide the Sequenom Center for
      Molecular Medicine (SCMM) with samples for a study to further evaluate
      its novel, noninvasive prenatal test to assess Down syndrome (Trisomy
      21) based on its circulating cell-free fetal (ccff) nucleic acid
      SEQureDx™ technology. Obstetrix is a national physician group practice
      of maternal-fetal medicine specialists that is affiliated with Pediatrix
      Medi...]]></description><category>Uncategorized</category><guid isPermaLink="false">1249459_NEWS</guid><pubDate>Wed, 28 Jan 2009 21:07:00 GMT</pubDate></item><item><title>Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1249186</link><description><![CDATA[    SAN DIEGO, Jan. 28 /PRNewswire-FirstCall/ -- (Nasdaq: SQNM) Analyst and
Investor Briefing and Reception



    What:     Sequenom: Defining the Future of Noninvasive Prenatal
              Diagnostics Analyst and Investor Briefing and Reception

    When:     Wednesday, January 28, 2009 from 5:30 p.m. to 8:00 p.m.
              Pacific Time

    Where:    www.sequenom.com/Corporate/Investor-Relations

    How:      Live over the Internet -- Simply log on to the Web at the
              address above.

    Contact:  Amy Higgins
              (310) 691-7100
              ahiggins@lhai.com


    About Sequenom
    Sequenom is committed to providing the best genetic ana...]]></description><category>Uncategorized</category><guid isPermaLink="false">1249186_NEWS</guid><pubDate>Wed, 28 Jan 2009 13:03:00 GMT</pubDate></item><item><title>Sequenom Terminates Exchange Offer to Acquire EXACT Sciences</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1249136</link><description><![CDATA[    SAN DIEGO--(BUSINESS WIRE)--Jan. 28, 2009--Sequenom, Inc. (NASDAQ:SQNM) today announced it is terminating its
      exchange offer to acquire all of the outstanding shares of common stock
      of EXACT Sciences Corporation (NASDAQ:EXAS) without accepting for
      exchange or exchanging any shares of EXACT Sciences common stock.
      Sequenom had previously announced that it would terminate the exchange
      offer if EXACT Sciences entered into any out-licensing agreement,
      collaboration or financial restructuring. Sequenom continues to be
      committed to building its oncology diagnostic franchise.
    

      About Sequenom
    

      Sequenom is committed to pr...]]></description><category>Uncategorized</category><guid isPermaLink="false">1249136_NEWS</guid><pubDate>Wed, 28 Jan 2009 12:01:00 GMT</pubDate></item><item><title>Sequenom Commences Exchange Offer to Acquire EXACT Sciences</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1248593</link><description><![CDATA[    SAN DIEGO--(BUSINESS WIRE)--Jan. 27, 2009--Sequenom, Inc. (NASDAQ: SQNM) today announced that it has
      commenced an exchange offer to acquire all of the outstanding shares of
      common stock of EXACT Sciences Corporation (NASDAQ: EXAS) in an
      all-stock exchange valued at approximately $41 million. Subject to the
      terms and conditions of the offer, each share of EXACT Sciences is
      exchangeable for $1.50 in Sequenom common stock, subject to a 15% collar
      that fixes the exchange ratio if the price of Sequenom common stock used
      to establish the exchange ratio is more than $28.06 per share or is less
      than $20.74 per share.
    

      "We cont...]]></description><category>Uncategorized</category><guid isPermaLink="false">1248593_NEWS</guid><pubDate>Tue, 27 Jan 2009 12:02:00 GMT</pubDate></item><item><title>Sequenom Expands Molecular Diagnostics Portfolio with Acquisition of SensiGen</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1248357</link><description><![CDATA[SensiGen Proprietary AttoSense(TM) Assays for HPV, Cervical Cancer and Other Diseases Complement Sequenom's Growing Noninvasive Test Portfolio
    SAN DIEGO & ANN ARBOR, Mich.--(BUSINESS WIRE)--Jan. 26, 2009--Sequenom, Inc. (NASDAQ:SQNM) announced an agreement to acquire the
      complete AttoSense(TM) portfolio of tests along with certain other assets
      from privately held biotechnology company SensiGen LLC. SensiGen has
      been developing advanced gene-based molecular tests with diagnostic
      potential under a partnership agreement with Sequenom. The acquisition
      includes analytically validated, ultra-sensitive and ultra-specific
      tests for detection and monitor...]]></description><category>Uncategorized</category><guid isPermaLink="false">1248357_NEWS</guid><pubDate>Mon, 26 Jan 2009 21:06:00 GMT</pubDate></item><item><title>Sequenom Names Allan T. Bombard, M.D., Chief Medical Officer</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1248043</link><description><![CDATA[    SAN DIEGO--(BUSINESS WIRE)--Jan. 26, 2009--Sequenom, Inc. (NASDAQ: SQNM) today announced that it has named
      Allan T. Bombard, M.D., to the newly created position of Chief Medical
      Officer. Dr. Bombard will oversee Sequenom's clinical and medical
      affairs, including clinical strategy, operations and clinical advocacy.
    

      "Allan has played an instrumental role in the development of our
      noninvasive prenatal diagnostic division, including serving as the
      principal investigator in a screening study to clinically assess the
      Company's noninvasive prenatal diagnostic technology for the detection
      of Down syndrome from a maternal blood sampl...]]></description><category>Uncategorized</category><guid isPermaLink="false">1248043_NEWS</guid><pubDate>Mon, 26 Jan 2009 12:01:00 GMT</pubDate></item><item><title>Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1246527</link><description><![CDATA[    SAN DIEGO, Jan. 20 /PRNewswire-FirstCall/ -- (Nasdaq: SQNM) Analyst and
Investor Briefing and Reception



    What:     Sequenom: Defining the Future of Noninvasive Prenatal
              Diagnostics Analyst and Investor Briefing and Reception



    When:     Wednesday, January 28, 2009 from 5:30 p.m. to 8:00 p.m.



    Where:    www.sequenom.com/Corporate/Investor-Relations



    How:      Live over the Internet -- Simply log on to the Web at the
              address above.



    Contact:  Amy Higgins

              (310) 691-7100

              ahiggins@lhai.com



    About Sequenom
    Sequenom is committed to providing the best genetic analysis products th...]]></description><category>Uncategorized</category><guid isPermaLink="false">1246527_NEWS</guid><pubDate>Wed, 21 Jan 2009 00:15:00 GMT</pubDate></item><item><title>Sequenom to Commence Exchange Offer to Acquire EXACT Sciences</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1244271</link><description><![CDATA[    SAN DIEGO--(BUSINESS WIRE)--Jan. 14, 2009--Sequenom, Inc. (NASDAQ:SQNM) announced that it intends to make an
      exchange offer to acquire all of the outstanding shares of common stock
      of EXACT Sciences Corporation (NASDAQ:EXAS) in an all-stock transaction
      valued at approximately $41 million. Under the terms of the proposal,
      each share of EXACT Sciences would be exchanged for $1.50 in Sequenom
      common stock. This consideration would be subject to a floating exchange
      rate within a 15% collar, in which the price of Sequenom's common stock
      is between $20.74 and $28.06 per share. The acquisition of EXACT
      Sciences, a pioneer in noninvasive st...]]></description><category>Uncategorized</category><guid isPermaLink="false">1244271_NEWS</guid><pubDate>Wed, 14 Jan 2009 09:01:00 GMT</pubDate></item><item><title>The Immune Tolerance Institute, Sequenom and the University of California, San Francisco to Develop Advanced Diagnostic Test for Severe Combined Immunodeficiency in Newborns</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1244130</link><description><![CDATA[Novel Technology Designed to Optimize Early Detection of Potentially Fatal Immune System Dysfunction in Infants
    SAN FRANCISCO & SAN DIEGO--(BUSINESS WIRE)--Jan. 13, 2009--The Immune Tolerance Institute, Inc. (ITI), and Sequenom, Inc. (NASDAQ:
      SQNM), today announced a collaboration to develop an advanced newborn
      screening test for severe combined immunodeficiency (SCID) based on the
      pioneering work of Jennifer Puck, MD, of the University of California,
      San Francisco (UCSF). A successful feasibility study was recently
      completed demonstrating the adaptability of Dr. Puck's RT-PCR screening
      assay for SCID diagnosis on the MassARRAY(R) platform devel...]]></description><category>Uncategorized</category><guid isPermaLink="false">1244130_NEWS</guid><pubDate>Tue, 13 Jan 2009 21:07:00 GMT</pubDate></item><item><title>Sequenom Proposes to Acquire EXACT Sciences for $1.50 Per Share or Approximately $41 Million</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1242680</link><description><![CDATA[Acquisition Would Enhance Sequenom's Position in Cancer Genomics and Noninvasive Cancer Diagnostics
Conference Call Begins at 9:00 a.m. Eastern Time Monday, January 12th
    SAN DIEGO--(BUSINESS WIRE)--Jan. 9, 2009--Sequenom, Inc. (NASDAQ:SQNM) announces that it has submitted a
      proposal to the Board of Directors of EXACT Sciences Corporation
      (NASDAQ:EXAS) to acquire all of the outstanding shares of common stock
      of EXACT Sciences in an all-stock transaction valued at approximately
      $41 million. Under the terms of the proposal, each share of EXACT
      Sciences would be exchanged for $1.50 in Sequenom common stock. This
      consideration would be subject to a ...]]></description><category>Uncategorized</category><guid isPermaLink="false">1242680_NEWS</guid><pubDate>Fri, 09 Jan 2009 21:26:00 GMT</pubDate></item><item><title>Sequenom to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 15</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1241892</link><description><![CDATA[    SAN DIEGO--(BUSINESS WIRE)--Jan. 8, 2009--Sequenom, Inc. (NASDAQ: SQNM), a leading provider of genetic analysis
      solutions, today announced that Harry Stylli, Ph.D., President and Chief
      Executive Officer, is scheduled to present at the 27th Annual
      J.P. Morgan Healthcare Conference on Thursday, January 15th
      at 11:00 a.m. Pacific time (2:00 p.m. Eastern time). The conference is
      being held at the Westin St. Francis Hotel in San Francisco.
    

      A live webcast of the presentation will be available on the Company's
      Web site at www.sequenom.com,
      and replays will be available for 14 days starting approximately three
      hours after the...]]></description><category>Uncategorized</category><guid isPermaLink="false">1241892_NEWS</guid><pubDate>Thu, 08 Jan 2009 09:01:00 GMT</pubDate></item><item><title>Next-Generation Noninvasive Diagnostic Technology Shown to Accurately Detect Fetal Down Syndrome in First Trimester of Pregnancy</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1231204</link><description><![CDATA[    SAN DIEGO--(BUSINESS WIRE)--Dec. 1, 2008--Sequenom, Inc. (NASDAQ:SQNM) announced new data from a
      collaborative project with The Chinese University of Hong Kong,
      published this week in the Early Edition of the Proceedings of the
      National Academy of Sciences, that demonstrate its innovative,
      next-generation, noninvasive prenatal diagnostic technology accurately
      quantified maternal plasma DNA sequences for fetal Trisomy 21, or Down
      syndrome, based on samples taken from women in the first and second
      trimesters of pregnancy. These data are the first to suggest that this
      future approach, based on massively parallel genomic DNA sequencing,...]]></description><category>Uncategorized</category><guid isPermaLink="false">1231204_NEWS</guid><pubDate>Mon, 01 Dec 2008 22:02:00 GMT</pubDate></item><item><title>New Noninvasive Prenatal Diagnostic Technology Allows Diagnosis of Inherited Diseases Such as Cystic Fibrosis Caused by Single Gene Mutations</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1229747</link><description><![CDATA[Novel 'Mutation Counting' Approach Allows the Precise Measurement of Multiple Disease-Causing Mutations Inherited by a FetusSAN DIEGO, Nov 24, 2008 (BUSINESS WIRE) -- Sequenom, Inc. (NASDAQ:SQNM), announced that breakthrough data 
      from a collaborative project with The Chinese University of Hong Kong, 
      supporting the noninvasive prenatal diagnosis of monogenic diseases, 
      were published online today in the Early Edition of the Proceedings 
      of the National Academy of Sciences. Monogenic diseases, which 
      include cystic fibrosis, B-thalassemia and sickle cell anemia, could 
      only be definitively diagnosed prenatally through invasive procedures 
      foll...]]></description><category>Uncategorized</category><guid isPermaLink="false">1229747_NEWS</guid><pubDate>Mon, 24 Nov 2008 22:06:00 GMT</pubDate></item><item><title>Sequenom Completes Acquisition of CLIA-Certified Laboratory</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1227167</link><description><![CDATA[Expands Capabilities to Cover All Aspects of SEQureDx Test Commercialization     SAN DIEGO, Nov 17, 2008 (BUSINESS WIRE) -- --Clears Way to Initiate SEQureDx Down Syndrome LDT Validation Study
Sequenom (NASDAQ: SQNM) today announced that it has completed the 
      previously announced acquisition of Grand Rapids, Michigan-based Center 
      for Molecular Medicine, a Clinical Laboratory Improvement Act (CLIA) 
      certified clinical diagnostics laboratory. As part of the acquisition, 
      Sequenom has formalized certain collaborative agreements with Spectrum 
      Health and the Van Andel Research Institute, which were joint venture 
      partners in the CLIA laboratory. The CL...]]></description><category>Uncategorized</category><guid isPermaLink="false">1227167_NEWS</guid><pubDate>Mon, 17 Nov 2008 13:04:00 GMT</pubDate></item><item><title>Sequenom Reports 2008 Third Quarter Financial Results</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1220146</link><description><![CDATA[
    Company Achieved Significant Milestones in Development of
                    Proprietary Down Syndrome Test;

                 Company Affirms 2008 Revenue Guidance

    SAN DIEGO--(BUSINESS WIRE)--Oct. 30, 2008--Sequenom, Inc.
(NASDAQ:SQNM), a leading provider of molecular diagnostic applications
and genetic analysis products and services, today reported financial
results for the three and nine months ended September 30, 2008.

    "During the third quarter we rapidly advanced our
paradigm-shifting approach to Down syndrome screening and reinforced
our significant leadership in the noninvasive prenatal diagnostics
space," stated Harry Stylli, Ph.D., President and Chief E...]]></description><category>Uncategorized</category><guid isPermaLink="false">1220146_NEWS</guid><pubDate>Thu, 30 Oct 2008 20:06:00 GMT</pubDate></item><item><title>Sequenom Announces Exclusive Licensing Agreement with Xenomics for Noninvasive Prenatal Diagnostics Using Transrenal DNA</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1219562</link><description><![CDATA[    SAN DIEGO--(BUSINESS WIRE)--Oct. 30, 2008--Sequenom, Inc. (NASDAQ:
SQNM), a leading provider of molecular diagnostic applications and
genetic analysis products and services, today announced that it has
licensed from Xenomics, Inc. (XNOM.PK), a developer of noninvasive
molecular diagnostic tests, exclusive rights to patents (U.S. Patents
6,251,638 and RE 39,920, European Patent EP 0920539) for prenatal
research and diagnostic products developed using fetal nucleic acids
found in maternal urine. Financial terms were not disclosed.

    "Sequenom's significant position in noninvasive prenatal
diagnostics is further enhanced by these patent rights," stated Harry
Stylli, Ph.D., Pre...]]></description><category>Uncategorized</category><guid isPermaLink="false">1219562_NEWS</guid><pubDate>Thu, 30 Oct 2008 10:01:00 GMT</pubDate></item><item><title>Sequenom Announces Launch of RNA-Based Noninvasive Aneuploidy (RNA) Study</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1218236</link><description><![CDATA[    Independent Study Will Document Performance of SEQureDx T21
         Technology for Down Syndrome in 10,000 Pregnant Women
    SAN DIEGO--(BUSINESS WIRE)--Oct. 28, 2008--Sequenom, Inc. (NASDAQ:
SQNM) today announced the launch of an independent, prospective,
multi-center observational study to document the performance of
Sequenom's SEQureDx(TM) Trisomy 21 technology for Down syndrome based
upon Sequenom's SEQureDx Technology. The study, RNA-based Noninvasive
Aneuploidy (RNA), will be directed by Jacob Canick, Ph.D., Professor
of Pathology and Laboratory Medicine, Brown University Medical School,
and Glenn Palomaki, Associate Director, Division of Medical Screening,
Women & Infa...]]></description><category>Uncategorized</category><guid isPermaLink="false">1218236_NEWS</guid><pubDate>Tue, 28 Oct 2008 11:31:00 GMT</pubDate></item><item><title>Sequenom to Hold 2008 Third Quarter Financial Results Conference Call on October 30</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1206965</link><description><![CDATA[    SAN DIEGO--(BUSINESS WIRE)--
Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic
analysis solutions, today announced that it will release 2008 third
quarter financial results after market close on Thursday, October 30,
2008. Sequenom management will host an investment-community conference
call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss
those results and answer questions.
    Individuals interested in participating in the conference call may
do so by dialing (866) 844-2998 for domestic callers, or (706)
679-9912 for international callers. Those interested in listening to
the conference call live via the Internet may do so by selecting
Investor Relatio...]]></description><category>Uncategorized</category><guid isPermaLink="false">1206965_NEWS</guid><pubDate>Wed, 08 Oct 2008 15:55:00 GMT</pubDate></item><item><title>Sequenom Announces Additional, Positive Results for Down Syndrome Test at Analyst Briefing</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1200347</link><description><![CDATA[    Management Joined by Leading Scientists and Clinicians to Discuss
            Study Results and Other Business Updates
    SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Sept. 23, 2008--Sequenom,
Inc. (NASDAQ:SQNM), a leading provider of genetic-analysis and
molecular diagnostic solutions, announced additional, positive results
from screening studies using the Company's noninvasive circulating
cell-free fetal (ccff) nucleic acid SEQureDx(TM) Technology, which
enables the detection of fetal aneuploidy, including Down syndrome
from maternal blood, at its Analyst Briefing in New York City. Among
the data presented, Sequenom's test demonstrated complete concordance
with clinical results (n...]]></description><category>Uncategorized</category><guid isPermaLink="false">1200347_NEWS</guid><pubDate>Tue, 23 Sep 2008 21:00:00 GMT</pubDate></item><item><title>Sequenom Announces Acquisition of CLIA-Certified Laboratory and Partnerships with Spectrum Health and Van Andel Research Institute</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1200148</link><description><![CDATA[
    Acquisition of Center for Molecular Medicine Positions Sequenom
     for Commercial Launch of SEQureDx(TM) Test in First Half 2009

       Daniel H. Farkas, Ph.D. to Join Sequenom Management Team

    SAN DIEGO--(BUSINESS WIRE)--Sept. 23, 2008--Sequenom (NASDAQ:SQNM)
today announced that it entered into an agreement to acquire the
Center for Molecular Medicine (CMM), a Clinical Laboratory Improvement
Act (CLIA) certified clinical diagnostics laboratory based in Grand
Rapids, Michigan. CMM is an innovative joint venture between Spectrum
Health, one of the largest not-for-profit health systems in Michigan,
and the Van Andel Research Institute, an independent research
institut...]]></description><category>Uncategorized</category><guid isPermaLink="false">1200148_NEWS</guid><pubDate>Tue, 23 Sep 2008 17:06:00 GMT</pubDate></item><item><title>Sequenom Announces Exclusive Licensing Agreement with Genomic Nanosystems for Digital PCR Technologies and Methods Patents</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1199153</link><description><![CDATA[    SAN DIEGO--(BUSINESS WIRE)--Sept. 22, 2008--Sequenom, Inc.
(Nasdaq: SQNM) today announced that it has secured exclusive rights to
fundamental patent rights for digital PCR technologies and methods
through a licensing agreement with Genomic Nanosystems, LLC, a wholly
owned subsidiary of the Cytonix Corporation. The exclusively licensed
rights include United States Patent Nos. 6,143,496 and 6,391,559 and
pending applications. The license provides Sequenom with the exclusive
right to use digital PCR methods on any platform for noninvasive
prenatal diagnostics and analysis for any sample (for example, fetal
cells, amniocentesis fluids, plasma, urine, etc.). Sequenom also
secured th...]]></description><category>Uncategorized</category><guid isPermaLink="false">1199153_NEWS</guid><pubDate>Mon, 22 Sep 2008 11:01:00 GMT</pubDate></item><item><title>Sequenom to Webcast Analyst and Investor Briefing Presentation on September 23</title><link>http://phx.corporate-ir.net/phoenix.zhtml?c=84955&amp;p=RssLanding&amp;cat=news&amp;id=1198527</link><description><![CDATA[    SAN DIEGO, Sept. 18 /PRNewswire-FirstCall/ -- Sequenom (Nasdaq: SQNM)
today announced that a live audio webcast and accompanying slide presentation
will be provided for its analyst and investor briefing event "Sequenom Analyst
and Investor Briefing."   Details of the event are as follows:


    What:     SEQUENOM ANALYST AND INVESTOR BRIEFING

    When:     Tuesday, September 23, 2008 at 4:30 p.m. Eastern time

    Where:    www.sequenom.com

    (Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)

    Agenda:
      Harry Stylli, Ph.D., Chief Executive Officer of Sequenom, Inc.
      "Sequenom Business Overview and Update"

      Presenters:
      Charles Can...]]></description><category>Uncategorized</category><guid isPermaLink="false">1198527_NEWS</guid><pubDate>Thu, 18 Sep 2008 13:03:00 GMT</pubDate></item></channel></rss>